Clinical Handbook of Psychotropic Drugs

The Clinical Handbook of Psychotropic Drugs has become a standard reference and working tool for psychiatrists, psychologists, physicians, pharmacists, nurses, and other mental health professionals. ? Independent, unbiased, up-to-date - now with esketamine (Spravato)? Packed with unique, easy-to-read comparison charts and tables (dosages, side effects, pharmacokinetics, interactions?) for a quick overview of treatment options? Expanded treatment options for extrapyramidal side effects include deutetrabenazine and valbenazine? New formulations and trade names include: Adzenys ER, Aristada, Austedo, Cotempla XR-ODT, Fanatrex FusePaq, Foquest, Ingrezza, Jornay PM, Mydayis, Nuplazid, Spravato, Sublocade, Zelapar? Succinct, bulleted information on all classes of medication: on- and off-label indications, side effects, interactions, pharmacodynamics, precautions in the young, the elderly, and pregnancy, nursing implications, and much more - all you need to know for each class of drug? Potential interactions and side effects summarized in comparison charts? With instantly recognizable icons and in full color throughout, allowing you to find at a glance all the information you seek? Clearly written patient information sheets available for download as printable PDF filesThis book is a must for everyone who needs an up-to-date, easy-to-use, comprehensive summary of all the most relevant information about psychotropic drugs.-------------------------------------------------------------------------------------------New in this edition:? Antidepressants chapter includes new section on esketamine (Spravato), recently approved for treatment-resistant depression; also updates to antidepressant use in pregnancy and SPARI drug interactions? Antipsychotics updates include new section on 5-HT2A inverse agonist antipsychotic (pimavanserin, Nuplazid) and comprehensive revision of augmentation strategies? Pharmacogenomics chapter fully revised with expanded dose adjustment recommendations? Chart of agents under investigation for treatment of substance use disorders fully revised, new agents include lofexidine (Lucemyra), Kadian, nortriptyline e-cigarettes? Unapproved treatments chapter with significant updates, including new sections on adrenergic agents in PTSD (doxazosin), antiflammatory agents in depression (pioglitazone, rosiglitazone, statins), and hormones in schizophrenia (raloxifene)? Expanded treatment options for extrapyramidal side effects include deutetrabenazine and valbenazine ? New formulations and trade names include: Adzenys ER, Aristada, Austedo, Cotempla XR-ODT, Fanatrex FusePaq, Foquest, Ingrezza, Jornay PM, Mydayis, Nuplazid, Spravato, Sublocade, Zelapar